4.7 Review

Phage-tail-like bacteriocins as a biomedical platform to counter anti-microbial resistant pathogens

Journal

BIOMEDICINE & PHARMACOTHERAPY
Volume 155, Issue -, Pages -

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2022.113720

Keywords

Bacteriocins; Phage; Multi-drug resistant pathogen; Anti-microbial activity; Phage tail-like bacteriocin

Funding

  1. DBT-BUILDER program at KIIT University [BT/INF/22/SP42155/2021]

Ask authors/readers for more resources

This review discusses the structural association, mechanism, and characterization of Phage Tail Like bacteriocins (PTLBs), as well as the symbiotic biological function and application of PTLBs against drug-resistant pathogens. The article also highlights the evolutionary role of PTLBs and the challenges that need to be addressed for clinical implementation.
Phage Tail Like bacteriocins (PTLBs) has been an area of interest in the last couple of years owing to their varied application against multi-drug resistant (MDR), anti-microbial resistant (AMR) pathogens and their evolutionary link with the dsDNA virus and bacteriophages. PTLBs are defective phages derived from Myoviridae and Sipho-viridae phages, PTLBs are distinguished into R-type (Rigid type) characterized by a non-flexible contractile nanotube resembling Myoviridae phage contractile tails, and F-type (Flexible type) with a flexible non-contractile rod-like structure similar to Siphoviridae phages. In this review, we have discussed the structural association, mechanism, and characterization of PTLBs. Moreover, we have elucidated the symbiotic biological function and application of PTLBs against MDR and XDR pathogens and highlighted the evolutionary role of PTLBs. The difficulties that must be overcome to implement PTLBs clinically are also discussed. It is imperative that these issues be addressed by academics in future studies before being implemented in clinical settings. This article is novel in its way as it will not only provide us with a gateway that acts as a novel strategy for scholars to mitigate and control the uprising issue of AMR pathogens but also promote the development of clinical studies for PTLBs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available